Given the augmented tumoricidal efficacy demonstrated by GEM@PLGA@HM invitro, we delved deeper into the underlying mechanisms responsible for its cancer-targeting and inhibitory capabilities, employing HER2+ 4T1 and SK-OV-3 cells as our model systems (Fig. 5A). Here, ERBB2 is linked to cancer.